Association Between Sarcopenia Index and Incident Cardiovascular Events in a Chinese Aging Population: Prospective Analysis of the CHARLS Study

中国老年人群中肌少症指数与心血管事件发生率的关联:CHARLS研究的前瞻性分析

阅读:2

Abstract

PURPOSE: The Sarcopenia Index (SI), derived from the serum creatinine to cystatin C ratio, is a potential biomarker for cardiovascular disease (CVD). However, its prognostic significance for incident CVD in aging Chinese populations remains insufficiently characterized, despite established links between sarcopenia and CVD progression. PATIENTS AND METHODS: This prospective cohort study utilized data from the China Health and Retirement Longitudinal Study (CHARLS). A total of 4979 participants aged > 45 years without prevalent CVD at baseline were included (mean age 58.0 years). Participants were categorized into Sarcopenia Index (SI) tertiles as follows: Q1 (SI ≤ 71.10), Q2 (71.10 < SI ≤ 84.75), and Q3 (SI > 84.75). Incident CVD events were assessed over a 9-year follow-up period. Multivariable Cox proportional hazards models, adjusted for demographic factors, comorbidities, and lipid profiles, were employed to evaluate associations. Restricted cubic spline (RCS) analysis was used to evaluate the dose-response relationship between SI and CVD risk. RESULTS: In the total population, the cumulative incidence of CVD was 23.5%. The lowest SI tertile (Q1) exhibited the highest cumulative CVD incidence (27.0%), compared to Q2 (23.2%) and Q3 (20.4%). After multivariable adjustment, individuals in Q1 showed a significantly increased risk of CVD compared to those in Q3 (HR: 1.249, 95% CI: 1.054, 1.478, P=0.010). RCS analysis confirmed a non-linear inverse association between SI and CVD risk (P for non-linearity = 0.003). Significant associations were particularly pronounced in males, current smokers, non-drinkers, urban residents, individuals with body mass index (BMI) ≥28 kg/m(2), and participants without hypertension or diabetes (all P < 0.05). CONCLUSION: Reduced SI independently predicts elevated CVD risk in aging adults, underscoring its potential as an accessible, cost-effective screening biomarker. Integration of SI into routine clinical assessments may enhance early risk stratification and guide targeted preventive strategies, particularly for high-risk subgroups.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。